• Delic opened two new KWC clinics in Q1 2022, bringing the total number of locations to 13, with plans to open more within the next 18 months
• The company also saw the introduction of SPRAVATO(R) nasal spray as a treatment option for treatment-resistant depression
• It is also expanding its ability to research novel compounds and develop IP for future commercialization

Delic Holdings’ (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Chief Executive Officer (“CEO”) and Co-founder, Matt Stang, has been keen to note the company’s commitment to bringing psychedelic medicine closer to individuals dealing with mental health conditions, particularly those with treatment-resistant anxiety, depression, or post-traumatic stress disorder (“PTSD”).

“Based on our survey results, the majority of affected Americans believe that psychedelic medicine should be made available to patients with treatment-resistant anxiety, depression or PTSD,” he said. “Our mission to make these new, science-backed medicines accessible and affordable to a greater number of people suffering from these conditions is more urgent than ever,” he added (https://ibn.fm/dNoyn).

This drive has prompted the opening of two new Ketamine Wellness Centers (“KWC”) within the first quarter of 2022, bringing the total number of clinics to 13. These two new clinics, located in Salt Lake City and Reno, promise to offer affordable treatment to the residents of Utah, Nevada, and the larger California markets.

In addition, the urgency has also seen an increase in KWC offerings, with the introduction of the SPRAVATO(R) nasal spray as a treatment option. SPRAVATO is the first FDA-approved esketamine nasal spray targeted toward adults with treatment-resistant depression (“TRD”). This esketamine is designed to be taken together with an oral antidepressant and has proven effective for the treatment of depressive symptoms in adults with major depressive disorder (“MDD”) with suicide actions or thoughts.

The company is also expanding its ability to explore novel compounds and develop intellectual property (“IP”) for future commercialization. These efforts have seen the addition of a Health Canada 56 exceptions for MDMA, LSD, DMT, mescaline, 2C-B, and the acquisition of 60 grams of psilocybin mushrooms from nectar Health Sciences Laboratory Division Inc.

Over the next 18 months, Delic plans to open more state-of-the-art clinics, bringing affordable treatment alternatives closer to the people. It is also planning to delve deeper into more research while pushing for more approvals to present even more treatment options to patients with mental health ailments. “Delic is opening doors to a future with more effective medicines for a variety of mental health conditions with longer lasting benefits and less side effects,” noted Mr. Stang.

For more information, visit the company’s website at www.DelicCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.